The recent update to Progyny’s analyst model reflects a higher Fair Value Estimate of US$36.17 compared with US$34.42, which informs how some investors may think about the stock’s price potential. That adjustment sits alongside Street research that mixes optimism around record Q3 2026 results and raised guidance with caution about utilization trends and visibility into 2026. As you read on, you will see how these shifting targets and narratives fit together and how to track Progyny’s evolving...
Progyny stock broke out past its latest buy point after the company's Q3 earnings surged 113% vs. year-ago period.
Progyny has delivered a sharp 56.1% share price gain over the past year, and that kind of run naturally raises a simple question for holders and onlookers alike. Is the current valuation still grounded in what the business is earning, or has the price moved ahead of its fundamentals? The 56.1% return over the last 12 months puts Progyny in a very different place from three and five years ago. This makes the current earnings based valuation question far more important for anyone considering...
More than 70% of members in the study reported symptom improvement, with the greatest gains among those receiving both personalized coaching and menopause-trained provider careNEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from a new clinical outcomes study showing significant improvements in menopause symptoms among members receiving care through its Menopause and Midlife program
Detailed price information for Progyny Inc (PGNY-Q) from The Globe and Mail including charting and trades.
Progyny (PGNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Progyny has delivered a mixed ride for shareholders, with the stock climbing over the past year but still showing a steep decline over five years. This puts a sharper spotlight on what investors are really paying for its earnings today. With that backdrop, the key issue is whether the current share price around US$27 fairly reflects the company’s profit engine. Over the past 5 years, Progyny’s share price has fallen 57.5%, which raises the question of whether the market is reassessing how...
Kevin K Gordon, Director, on September 10, 2026, sold 11,500 shares in Progyny (PGNY) for $321,358.
Let’s dig into the relative performance of Progyny (NASDAQ:PGNY) and its peers as we unravel the now-completed Q2 health insurance providers earnings season.
This is the newest page. Registered accounts read further back.